ELDN / Eledon Pharmaceuticals, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5

Eledon Pharmaceuticals, Inc.
US ˙ NasdaqCM ˙ US28617K1016

Acțiuni restante 77,187,823 shares
Acțiuni Insider27.921.493 shares
Proprietatea din interior36,17 %
Total Insiders49
Scorul de sentimente din interior

Insider Sentiment Score găsește companiile cumpărate de persoane din interior.

Este rezultatul unui model cantitativ sofisticat, multifactorial, care identifică companiile cu cele mai înalte niveluri de acumulare de persoane interne. Modelul de scoring folosește o combinație a numărului net de persoane din interior care cumpără în ultimele 90 de zile, totalul acțiunilor cumpărate ca procent din flota și totalul acțiunilor deținute de insider. Numărul variază de la 0 la 100, numerele mai mari indicând un nivel mai ridicat de acumulare pentru semenii săi, iar 50 fiind media.

Frecvența actualizării: zilnic

Vedeți Top Picks Insiders, care oferă o listă a companiilor cu cea mai mare acumulare de persoane din interior.

Scorul de sentiment al ofițerului

Scorul de sentiment al ofițerilor găsește companii cumpărate de ofițerii corporativi.

Prin definiție, Ofițerii Corporativi sunt Corporate Insiders, dar spre deosebire de unii dintre ceilalți Insiders (10% Acționari și Membri ai Consiliului de Administrație), Ofițerii lucrează zilnic pentru companie și își folosesc banii atunci când tranzacționează . (10% acționari și membri ai consiliului de administrație sunt adesea administratori de fonduri care gestionează banii altor persoane.) Ca atare, tranzacțiile privilegiate efectuate de către ofițeri sunt mult mai semnificative și ar trebui tratate în mod corespunzător.

La fel ca Scorul Sentimentului Insider, Scorul Sentimentului Ofițerului este rezultatul unui model cantitativ sofisticat, multifactorial, care identifică companiile cu cele mai înalte niveluri de acumulare de ofițeri.

Frecvența actualizării: zilnic

Vedeți Top Picks Insiders, care oferă o listă a companiilor cu cel mai mare sentiment din interior.

Valori cheie ale insiderului

Acest card arată modul în care compania se clasifică de-a lungul diferitelor valori interne. Clasamentul percentilei arată cum se compară această companie cu alte companii de pe piețele din SUA. Clasamentele mai înalte indică situații mai bune.

De exemplu, este în general acceptat că cumpărarea din interior este un indicator pozitiv, astfel încât companiile cu mai multe achiziții din interior s-ar clasa mai sus decât companiile cu mai puține achiziții din interior (sau chiar vânzări din interior).

Numărul net de persoane din interior care cumpără (clasament)

0 ( )
2579 out of 10931

Numărul net de persoane din interior care cumpără este numărul total de persoane din interior care cumpără minus numărul total de persoane din interior care au vândut în ultimele 90 de zile. Rangul percentilei este afișat aici (interval de la 0 la 100%).

Procent din flota cumpărată de persoane din interior (clasament)

0.000% ( )
2568 out of 10786

Procent of Float Bought by Insiders este numărul total de acțiuni cumpărate de insiders minus numărul total de acțiuni vândute de insiders în ultimele 90 de zile, împărțit la flota totală și înmulțit cu 100.

Graficul privind tranzacțiile privilegiate

Eledon Pharmaceuticals, Inc. tranzacții privilegiate sunt prezentate în graficul următor. Insiders sunt ofițeri, directori sau investitori importanți într-o companie. În general, este în general ilegal ca persoanele din interior să facă tranzacții în companiile lor pe baza unor informații materiale, nepublice. Acest lucru nu înseamnă că este ilegal pentru ei să facă tranzacții în propriile companii. Cu toate acestea, ei trebuie să raporteze toate tranzacțiile către SEC printr-un Formular 4.

Lista de persoane din interior și valori de profitabilitate

Acest tabel prezintă lista persoanelor din interior cunoscute și este generată automat din dosarele dezvăluite SEC. Pe lângă nume, cel mai recent titlu și desemnarea directorului, a ofițerului sau a proprietarului în proporție de 10%, oferim cele mai recente dețineri divulgate. În plus, atunci când este posibil, oferim performanța comercială istorică pentru persoane din interior. Performanța comercială istorică este o medie ponderată a performanței tranzacțiilor reale de cumpărare pe piață deschisă efectuate de către insider. Pentru mai multe informații despre cum se calculează, urmăriți acest webinar YouTube.

See our leaderboard of most profitable insider traders.

Insider Profit mediu (%) Acțiuni
Deținut
Despică
Ajustat
Apple Tree Partners Ii Lp Director, 10% Owner - [D] [10%] 4.218.641 4.218.641
Apple Tree Partners II - Annex, L.P. Director, 10% Owner - [D] [10%] 3.568.438 3.568.438
Apple Tree Partners IV, L.P. Director, 10% Owner - [D] [10%] 250.000 250.000
Timothy J Barberich Director - [D] 121.077 121.077
Biotechnology Value Fund Ii Lp - 113.152 220.460
Biotechnology Value Fund L P - 113.152 220.460
Bvf Gp Holdings Llc 10% Owner - [10%] 113.152 220.460
Bvf I Gp Llc - 113.152 220.460
Bvf Ii Gp Llc - 113.152 220.460
Bvf Inc/il 10% Owner - [10%] 113.152 220.460
Bvf Partners L P/il 10% Owner - [10%] 220.460 220.460
BVF Partners OS Ltd. - 113.152 220.460
Biotechnology Value Trading Fund OS LP - 113.152 220.460
Buckley Stephen Jr. Director - [D] 11.000 11.000
Erez Chimovits Director - [D] 3.183.314 3.183.314
Cheryl Cohen Director - [D] 0 0
Insider Profit mediu (%) Acțiuni
Deținut
Despică
Ajustat
Flesher Gregory J. Chief Executive Officer, Director - [D] [O] 156.918 156.918
Karen Jean Ferrante 62.000
David-Alexandre C Gros Chief Executive Officer, Director - [D] [O] 9.000 9.000
Seth Loring Harrison Director, 10% Owner - [D] [10%] 7.912.079 7.912.079
Jan Hillson Director - [D] 3.430 3.430
Lee Kalowski Chief Financial Officer - [O] 40.953 40.953
Keith Katkin Director - [D] 8.575 8.575
Kessler David A. 12.000
Allan Kirk Director - [D] 3.430 3.430
Jon Kuwahara See Remarks - [O] 5.974 5.974
Mark N Lampert 10% Owner - [10%] 113.152 220.460
Lifesci Index Partners Llc 10% Owner - [10%] 1.065.867 1.065.867
Gary A Lyons Director - [D] 0 0
June Lee Director - [D] 3.430 3.430
Paul Sean Little CHIEF FINANCIAL OFFICER - [O] 10.000 10.000
Logos Global Management LP 10% Owner - [10%] 224.071 224.071
Insider Profit mediu (%) Acțiuni
Deținut
Despică
Ajustat
McBride John S. Director - [D] 3.430 3.430
Jodie Pope Morrison President and CEO, Director - [D] [O] 57.566 57.566
Ag Novartis 10% Owner - [10%] 4.493.458 4.493.458
Bioventures Ltd Novartis 10% Owner - [10%] 4.493.458 4.493.458
Christine Ocampo See Remarks - [O] 23.160 23.160
Walter C Ogier 20.000
OrbiMed Israel BioFund GP Limited Partnership Director, 10% Owner - [D] [10%] 73.650 73.650
OrbiMed Israel GP Ltd. 10% Owner - [10%] 73.650 73.650
Steven Perrin President, Director - [D] [O] 1.000 1.000
Gerald E Quirk 62.000
Robinson James A. Jr. Director - [D] 3.430 3.430
Muneer A Satter 10% Owner - [10%] 1.771.688 1.771.688
Smith Bryan E. 120.000
Turkel Catherine C. President - [O] 88.662 88.662
Martin D Williams 10% Owner - [10%] 337.700 337.700
Paul Yook 10% Owner - [10%] 1.065.867 1.065.867
Yanchik Joseph A., III Director - [D] 51.092 51.092

Report errors via our new Insider Auditing Tool

Înregistrări ale achizițiilor interne - Analiza profitului pe termen scurt

În această secțiune, analizăm profitabilitatea fiecărei achiziții neplanificate, pe piață deschisă, efectuată în ELDN / Eledon Pharmaceuticals, Inc.. Această analiză ajută la înțelegerea dacă persoana din interior generează în mod constant profituri anormale și merită urmărită. Această analiză este pentru un an după fiecare tranzacție și rezultatele sunt teoretice .

Următorul tabel prezintă cele mai recente achiziții pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.

Data tranzacției Insider Raportat
Acțiuni
Raportat
Preț
Ajustat
Acțiuni
Ajustat
Preț
Baza costurilor Zile pentru
Max
Pret la
Max
Max
Profit ($)
Randament maxim (%)
2024-05-09 BVF PARTNERS L P/IL 1.031.385 1.031.385 176 5.3000
2024-05-09 BVF PARTNERS L P/IL 821.121 821.121
2024-05-09 BVF PARTNERS L P/IL 75.431 75.431
2023-05-05 BVF PARTNERS L P/IL 1.055.445 1.055.445
2023-05-05 BVF PARTNERS L P/IL 837.146 837.146
2023-05-05 BVF PARTNERS L P/IL 86.341 86.341
2022-11-23 Perrin Steven 1.000 2,5969 1.000 2,5969 2.597
2021-12-20 Gros David-Alexandre C 2.000 4,4800 2.000 4,4800 8.960
2021-08-17 Gros David-Alexandre C 4.000 6,2100 4.000 6,2100 24.840

Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate reprezintă acțiunile ajustate în funcție de divizarea.

ELDN / Eledon Pharmaceuticals, Inc. Insider Trades
Înregistrări ale vânzărilor din interior - Analiza pierderilor pe termen scurt

În această secțiune, analizăm evitarea pierderilor pe termen scurt a fiecărei vânzări neplanificate, pe piață deschisă, efectuată în ELDN / Eledon Pharmaceuticals, Inc.. Un model consistent de evitare a pierderilor poate sugera că viitoarele tranzacții de vânzare pot prezice scăderi ale prețului. Această analiză este pentru un an după fiecare tranzacție și rezultatele sunt teoretice .

Următorul tabel arată cele mai recente vânzări pe piața deschisă care nu făceau parte dintr-un plan de tranzacționare automată.

Data tranzacției Insider Raportat
Acțiuni
Raportat
Preț
Ajustat
Acțiuni
Ajustat
Preț
Baza costurilor Zile pentru
Min
Pret la
Min
Pierdere maximă
Evitat ($)
Pierdere maximă
Evitat (%)
2020-12-02 OrbiMed Israel GP Ltd. 103.200 21,6000 103.200 21,6000 2.229.120 22 13.8100 -803.928 -36,06
2020-10-30 Logos Global Management LP 27 27,0200 27 27,0200 730
2020-10-30 Logos Global Management LP 12.942 26,6442 12.942 26,6442 344.829
2019-05-21 TURKEL CATHERINE C. 1.914 1,9114 106 34,4052 3.658
2019-05-21 FLESHER GREGORY J. 2.937 1,9114 163 34,4052 5.614

Prețul ajustat este prețul ajustat în divizarea. Acțiunile ajustate reprezintă acțiunile ajustate în funcție de divizarea.

ELDN / Eledon Pharmaceuticals, Inc. Insider Trades
Istoricul tranzactiilor

Faceți clic pe pictograma link pentru a vedea istoricul complet al tranzacțiilor. Tranzacțiile raportate ca parte a unui plan de tranzacționare automată 10b5-1 vor avea un X în coloana marcată 10b-5.

Fişier
Data
Comerț
Data
Formă Insider Ticker Titlul de securitate Cod 10b5-1 Direct Exercițiu
Preț
Unitate
Preț
Unități
Schimbat
Valoare
Schimbat (1K)
Rămas
Opțiuni
Rămas
Acțiuni
2026-01-16 2026-01-10 4 Robinson James A. Jr. ELDN Common Stock M - Exercise D 3.430 3.430
2026-01-16 2026-01-10 4 Lee June ELDN Common Stock M - Exercise D 3.430 3.430
2026-01-16 2026-01-10 4 Katkin Keith ELDN Common Stock M - Exercise D 8.575 8.575
2026-01-16 2026-01-10 4 Kirk Allan ELDN Common Stock M - Exercise D 3.430 3.430
2026-01-16 2026-01-10 4 Hillson Jan ELDN Common Stock M - Exercise D 3.430 3.430
2026-01-16 2026-01-10 4 McBride John S. ELDN Common Stock M - Exercise D 3.430 3.430
2024-05-13 2024-05-09 4 BVF PARTNERS L P/IL ELDN Common Stock, $0.001 par value P - Purchase D 75.431 220.460
2024-05-13 2024-05-09 4 BVF PARTNERS L P/IL ELDN Common Stock, $0.001 par value P - Purchase D 821.121 2.633.679
2024-05-13 2024-05-09 4 BVF PARTNERS L P/IL ELDN Common Stock, $0.001 par value P - Purchase D 1.031.385 3.361.803
2023-05-09 2023-05-05 4 BVF PARTNERS L P/IL ELDN Common Stock, $0.001 par value P - Purchase D 86.341 145.029
2023-05-09 2023-05-05 4 BVF PARTNERS L P/IL ELDN Common Stock, $0.001 par value P - Purchase D 837.146 1.812.558
2023-05-09 2023-05-05 4 BVF PARTNERS L P/IL ELDN Common Stock, $0.001 par value P - Purchase D 1.055.445 2.330.418
2022-11-23 2022-11-23 4 Perrin Steven ELDN Common Stock P - Purchase D 2,5969 1.000 3 1.000
2022-02-02 2022-02-01 4 Gros David-Alexandre C ELDN Stock Option (right to buy) A - Award D 3,97 108.000 108.000
2022-02-02 2022-02-01 4 Smith Bryan E. ELDN Stock Option (right to buy) A - Award D 3,97 120.000 120.000
2022-02-02 2022-02-01 4 Ogier Walter C ELDN Stock Option (right to buy) A - Award D 3,97 20.000 20.000
2022-02-02 2022-02-01 4 Perrin Steven ELDN Stock Option (right to buy) A - Award D 3,97 155.000 155.000
2022-02-02 2022-02-01 4 McBride John S. ELDN Stock Option (right to buy) A - Award D 3,97 20.000 20.000
2022-02-02 2022-02-01 4 LYONS GARY A ELDN Stock Option (right to buy) A - Award D 3,97 20.000 20.000
2022-02-02 2022-02-01 4 Lee June ELDN Stock Option (right to buy) A - Award D 3,97 20.000 20.000
2022-02-02 2022-02-01 4 Hillson Jan ELDN Stock Option (right to buy) A - Award D 3,97 20.000 20.000
2022-02-02 2022-02-01 4 Katkin Keith ELDN Stock Option (right to buy) A - Award D 3,97 20.000 20.000
2022-02-02 2022-02-01 4 Little Paul Sean ELDN Stock Option (right to buy) A - Award D 3,97 155.000 155.000
2022-01-31 3 LAMPERT MARK N ELDN Common Stock, $0.001 par value D 975.412
2022-01-31 3 LAMPERT MARK N ELDN Common Stock, $0.001 par value D 1.274.973
2022-01-31 3 LAMPERT MARK N ELDN Common Stock, $0.001 par value D 58.688
2021-12-21 2021-12-20 4 Gros David-Alexandre C ELDN Common Stock P - Purchase D 4,4800 2.000 9 9.000
2021-08-19 2021-08-17 4 Gros David-Alexandre C ELDN Common Stock P - Purchase D 6,2100 4.000 25 7.000
2021-06-14 2021-06-11 4 Little Paul Sean ELDN Common Stock P - Purchase D 8,8700 10.000 89 10.000
2021-06-10 2021-06-09 4 Gros David-Alexandre C ELDN Common Stock P - Purchase D 8,0100 3.000 24 3.000
2021-05-04 2021-05-03 4 Smith Bryan E. ELDN Stock Option (Right to Buy) A - Award D 9,91 158.500 158.500
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Series X1 Convertible Preferred Stock C - Conversion D -1.757 6.758
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Series X1 Convertible Preferred Stock C - Conversion D -9.169 39.693
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Series X1 Convertible Preferred Stock C - Conversion D -11.776 52.145
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Series X Convertible Preferred C - Conversion D -35 0
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Series X Convertible Preferred C - Conversion D -203 0
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Series X Convertible Preferred C - Conversion D -273 0
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Common Stock, $0.001 par value C - Conversion D 97.615 113.152
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Common Stock, $0.001 par value C - Conversion D 1.944 15.537
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Common Stock, $0.001 par value C - Conversion D 509.410 598.624
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Common Stock, $0.001 par value C - Conversion D 11.278 89.214
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Common Stock, $0.001 par value C - Conversion D 654.215 771.780
2020-12-28 2020-12-22 4 BVF PARTNERS L P/IL NVUS Common Stock, $0.001 par value C - Conversion D 15.166 117.565
2020-12-04 2020-12-02 4 OrbiMed Israel GP Ltd. See Footnotes NVUS Common Stock S - Sale I 21,6000 -103.200 -2.229 73.650
2020-11-06 2020-10-30 4 Logos Global Management LP See Notes 1 and 2 NVUS Common Stock P - Purchase I 25,5507 9.098 232 224.071
2020-11-06 2020-10-30 4 Logos Global Management LP See Notes 1 and 2 NVUS Common Stock P - Purchase I 26,1740 15.000 393 214.973
2020-11-06 2020-10-30 4 Logos Global Management LP See Notes 1 and 2 NVUS Common Stock S - Sale I 27,0200 -27 -1 199.973
2020-11-06 2020-10-30 4 Logos Global Management LP See Notes 1 and 2 NVUS Common Stock P - Purchase I 25,8790 12.942 335 200.000
2020-11-06 2020-10-30 4 Logos Global Management LP See Notes 1 and 2 NVUS Common Stock S - Sale I 26,6442 -12.942 -345 187.058
2020-11-06 2020-10-30 4 Logos Global Management LP See Notes 1 and 2 NVUS Common Stock P - Purchase I 26,4824 15.000 397 200.000
2020-11-06 2020-10-30 4 Logos Global Management LP See Notes 1 and 2 NVUS Common Stock P - Purchase I 25,9730 4.000 104 185.000
2020-11-06 2020-10-30 4 Logos Global Management LP See Notes 1 and 2 NVUS Common Stock P - Purchase I 24,5299 31.000 760 181.000
2020-11-06 2020-10-30 4 Logos Global Management LP See Notes 1 and 2 NVUS Common Stock P - Purchase I 24,0325 5.000 120 150.000
2020-11-06 3 Logos Global Management LP See Notes 1 and 2 NVUS Common Stock I 145.000
2020-10-05 3 LAMPERT MARK N NVUS Common Stock D 77.936
2020-10-05 3 LAMPERT MARK N NVUS Common Stock D 102.400
2020-10-05 3 LAMPERT MARK N NVUS Common Stock D 13.595
2020-09-15 2020-09-11 4 LYONS GARY A NVUS Stock Option (Right to Buy) A - Award D 500,00 1.167 1.167
2020-09-15 2020-09-11 4 McBride John S. NVUS Stock Option (Right to Buy) A - Award D 500,00 1.167 1.167
2020-09-15 2020-09-11 4 Kuwahara Jon NVUS Stock Option (Right to Buy) A - Award D 500,00 2.145 2.145
2020-09-15 2020-09-11 4 Katkin Keith NVUS Stock Option (Right to Buy) A - Award D 500,00 5.907 5.907
2020-09-15 2020-09-11 4 Gros David-Alexandre C NVUS Stock Option (Right to Buy) A - Award D 500,00 18.278 18.278
2020-03-20 2020-03-19 4 Kuwahara Jon NVUS Stock Option (Right to Buy) A - Award D 0,26 50.000 50.000
2020-03-20 2020-03-19 4 TURKEL CATHERINE C. NVUS Stock Option (Right to Buy) A - Award D 0,26 100.000 100.000
2020-03-20 2020-03-19 4 FLESHER GREGORY J. NVUS Stock Option (Right to Buy) A - Award D 0,26 200.000 200.000
2020-02-25 2020-01-14 4 Chimovits Erez See Footnotes NVUS Warrants to Purchase Common Stock S - Sale I 0,2000 646.204 129 0
2020-02-25 2020-01-14 4 Chimovits Erez See Footnotes NVUS Warrants to Purchase Common Stock S - Sale I 0,2000 646.204 129 0
2020-02-25 2020-01-14 4 OrbiMed Israel GP Ltd. See Footnotes NVUS Warrants to Purchase Common Stock S - Sale I 0,2000 646.204 129
2020-02-25 2020-01-14 4 OrbiMed Israel GP Ltd. See Footnotes NVUS Warrants to Purchase Common Stock S - Sale I 0,2000 646.204 129
2019-09-30 2019-09-26 4 FLESHER GREGORY J. NVUS Stock Option (Right to Buy) A - Award D 0,67 100.000 100.000
2019-09-30 2019-09-26 4 TURKEL CATHERINE C. NVUS Stock Option (Right to Buy) A - Award D 0,67 75.000 75.000
2019-09-30 2019-09-26 4 Kuwahara Jon NVUS Stock Option (Right to Buy) A - Award D 0,67 60.000 60.000
2019-07-15 2019-07-11 4 Chimovits Erez NVUS Stock Option (Right to Buy) A - Award D 0,88 20.000 20.000
2019-07-15 2019-07-11 4 Katkin Keith NVUS Stock Option (Right to Buy) A - Award D 0,88 20.000 20.000
2019-07-15 2019-07-11 4 McBride John S. NVUS Stock Option (Right to Buy) A - Award D 0,88 20.000 20.000
2019-07-15 2019-07-11 4 Cohen Cheryl NVUS Stock Option (Right to Buy) A - Award D 0,88 20.000 20.000
2019-07-15 2019-07-11 4 LYONS GARY A NVUS Stock Option (Right to Buy) A - Award D 0,88 20.000 20.000
2019-05-22 2019-05-21 4 FLESHER GREGORY J. NVUS Common Stock S - Sale D 1,9114 -2.937 -6 156.918
2019-05-22 2019-05-20 4 FLESHER GREGORY J. NVUS Common Stock S - Sale D 1,9616 -11.701 -23 159.855
2019-05-22 2019-05-21 4 Kuwahara Jon NVUS Common Stock S - Sale D 1,9114 -1.058 -2 5.974
2019-05-22 2019-05-20 4 Kuwahara Jon NVUS Common Stock S - Sale D 1,9616 -4.218 -8 7.032
2019-05-22 2019-05-21 4 TURKEL CATHERINE C. NVUS Common Stock S - Sale D 1,9114 -1.914 -4 88.662
2019-05-22 2019-05-20 4 TURKEL CATHERINE C. NVUS Common Stock S - Sale D 1,9616 -7.623 -15 90.576
2019-05-06 2019-05-02 4 Chimovits Erez See Footnotes NVUS Warrants to Purchase Common Stock P - Purchase I 646.204 646.204
2019-05-06 2019-05-02 4 Chimovits Erez See Footnotes NVUS Warrants to Purchase Common Stock P - Purchase I 646.204 646.204
2019-05-06 2019-05-02 4 Chimovits Erez NVUS Common Stock P - Purchase I 3,1000 646.204 2.003 3.183.314
2019-05-06 2019-05-02 4 OrbiMed Israel GP Ltd. See Footnotes NVUS Warrants to Purchase Common Stock P - Purchase I 646.204 646.204
2019-05-06 2019-05-02 4 OrbiMed Israel GP Ltd. See Footnotes NVUS Warrants to Purchase Common Stock P - Purchase I 646.204 646.204
2019-05-06 2019-05-02 4 OrbiMed Israel GP Ltd. See Footnotes NVUS Common Stock P - Purchase I 3,1000 646.204 2.003 3.183.314
2019-05-02 2019-04-30 4 LIFESCI INDEX PARTNERS LLC NVUS Common Stock, par value $0.01 per share S - Sale I 2,7000 -200 -1 1.065.867
2019-03-18 2019-03-14 4 Kuwahara Jon NVUS Stock Option (Right to Buy) A - Award D 3,72 25.000 25.000
2019-03-18 2019-03-14 4 FLESHER GREGORY J. NVUS Stock Option (Right to Buy) A - Award D 3,72 90.000 90.000
2019-03-18 2019-03-14 4 FLESHER GREGORY J. NVUS Common Stock A - Award D 25.000 171.556
2019-03-18 2019-03-14 4 TURKEL CATHERINE C. NVUS Stock Option (Right to Buy) A - Award D 3,72 50.000 50.000
2019-03-18 2019-03-14 4 TURKEL CATHERINE C. NVUS Common Stock A - Award D 20.000 98.199
2018-09-13 2018-09-12 4 TURKEL CATHERINE C. NVUS Common Stock P - Purchase D 5,0190 16.632 83 78.199
2018-09-13 2018-09-11 4 TURKEL CATHERINE C. NVUS Common Stock P - Purchase D 4,5560 17.048 78 61.567
2018-09-07 2018-09-05 4 TURKEL CATHERINE C. By Spouse's IRA NVUS Common Stock P - Purchase I 3,9660 805 3 805
2018-06-14 2018-06-13 4 McBride John S. NVUS Stock Option (Right to Buy) A - Award D 6,18 9.100 9.100
2018-06-14 2018-06-13 4 Katkin Keith NVUS Stock Option (Right to Buy) A - Award D 6,18 9.100 9.100
2018-06-14 2018-06-13 4 LYONS GARY A NVUS Stock Option (Right to Buy) A - Award D 6,18 9.100 9.100
2018-06-14 2018-06-13 4 Cohen Cheryl NVUS Stock Option (Right to Buy) A - Award D 6,18 9.100 9.100
2018-03-20 3 LIFESCI INDEX PARTNERS LLC NVUS Common Stock, $.001 par value I 2.132.134
2018-03-20 3 LIFESCI INDEX PARTNERS LLC NVUS Common Stock, $.001 par value I 2.132.134
2018-03-20 3 LIFESCI INDEX PARTNERS LLC NVUS Common Stock, $.001 par value I 2.132.134
2018-03-20 3 LIFESCI INDEX PARTNERS LLC NVUS Common Stock, $.001 par value I 2.132.134
2018-03-15 2018-03-13 4 TURKEL CATHERINE C. NVUS Stock Option (Right to Buy) A - Award D 4,83 24.000 24.000
2018-03-15 2018-03-13 4 TURKEL CATHERINE C. NVUS Common Stock A - Award D 20.000 44.519
2018-03-15 2018-03-13 4 FLESHER GREGORY J. NVUS Stock Option (Right to Buy) A - Award D 4,83 56.500 56.500
2018-03-15 2018-03-13 4 FLESHER GREGORY J. NVUS Common Stock A - Award D 30.700 146.556
2018-03-15 2018-03-13 4 Kuwahara Jon NVUS Stock Option (Right to Buy) A - Award D 4,83 12.000 12.000
2018-03-15 2018-03-13 4 Kuwahara Jon NVUS Common Stock A - Award D 11.250 11.250
2017-11-06 2017-11-06 4 TURKEL CATHERINE C. NVUS Stock Option (Right to Buy) A - Award D 4,21 50.000 50.000
2017-07-10 2017-07-10 4 Kuwahara Jon NVUS Stock Option (Right to Buy) A - Award D 5,61 35.000 35.000
2017-07-05 2017-06-30 4 Katkin Keith NVUS Stock Option (Right to Buy) A - Award D 5,85 36.000 36.000
2017-07-05 2017-06-30 4 Morrison Jodie Pope NVUS Stock Option (Right to Buy) A - Award D 5,85 18.000 18.000
2017-07-05 2017-06-30 4 Cohen Cheryl NVUS Stock Option (Right to Buy) A - Award D 5,85 18.000 18.000
2017-07-05 2017-06-30 4 McBride John S. NVUS Stock Option (Right to Buy) A - Award D 5,85 18.000 18.000
2017-07-05 2017-06-30 4 LYONS GARY A NVUS Stock Option (Right to Buy) A - Award D 5,85 18.000 18.000
2017-05-26 2017-05-24 4 OCAMPO CHRISTINE NVUS Stock Option (Right to Buy) A - Award D 5,50 52.500 52.500
2017-05-26 2017-05-24 4 TURKEL CATHERINE C. NVUS Stock Option (Right to Buy) A - Award D 5,50 52.500 52.500
2017-05-26 2017-05-24 4 FLESHER GREGORY J. NVUS Stock Option (Right to Buy) A - Award D 5,50 250.000 250.000
2017-05-11 3 LYONS GARY A NVUS No Securities Owned D 0
2017-05-11 3 FLESHER GREGORY J. NVUS Common Stock D 113.794
2017-05-11 3 FLESHER GREGORY J. NVUS Common Stock D 113.794
2017-05-11 3 TURKEL CATHERINE C. NVUS Common Stock D 26.816
2017-05-11 3 TURKEL CATHERINE C. NVUS Common Stock D 26.816
2017-05-11 3 Katkin Keith NVUS Common Stock D 24.238
2017-05-11 3 Katkin Keith NVUS Common Stock D 24.238
2017-05-11 3 OCAMPO CHRISTINE NVUS Common Stock D 23.160
2017-05-11 3 OCAMPO CHRISTINE NVUS Common Stock D 23.160
2017-05-11 3 Chimovits Erez By OrbiMed Israel GP Ltd. NVUS Common Stock I 5.074.220
2017-05-11 3 Chimovits Erez By OrbiMed Israel GP Ltd. NVUS Common Stock I 5.074.220
2017-05-11 2017-05-10 4 FLESHER GREGORY J. NVUS Common Stock P - Purchase D 9,9900 58.959 589 115.856
2017-05-11 2017-05-10 4 OCAMPO CHRISTINE NVUS Common Stock P - Purchase D 9,9900 10.010 100 21.590
2017-05-11 2017-05-10 4 TURKEL CATHERINE C. NVUS Common Stock P - Purchase D 9,9900 11.111 111 24.519
2017-05-11 2017-05-09 4 OrbiMed Israel GP Ltd. See Footnotes NVUS Common Stock A - Award I 2.537.110 2.537.110
2016-06-16 2016-06-15 4 BARBERICH TIMOTHY J TKAI Stock Option (right to buy) A - Award D 6,29 12.000 12.000
2016-06-16 2016-06-15 4 Harrison Seth Loring TKAI Stock Option (right to buy) A - Award D 6,29 12.000 12.000
2016-06-16 2016-06-16 4 Cohen Cheryl TKAI Stock Option (right to buy) A - Award D 6,29 12.000 12.000
2016-06-16 2016-06-15 4 Buckley Stephen Jr. TKAI Stock Option (right to buy) A - Award D 6,29 12.000 12.000
2016-06-16 2016-06-15 4 Yanchik Joseph A., III TKAI Stock Option (right to buy) A - Award D 6,29 12.000 12.000
2016-06-16 2016-06-15 4 Kessler David A. TKAI Stock Option (right to buy) A - Award D 6,29 12.000 12.000
2016-03-15 2016-03-15 4 Buckley Stephen Jr. TKAI Common Stock P - Purchase D 5,7400 8.000 46 11.000
2016-01-08 2016-01-08 4 Morrison Jodie Pope TKAI Stock Option (right to buy) M - Exercise D 1,37 -20.000 37.878
2016-01-08 2016-01-08 4 Morrison Jodie Pope TKAI Stock Option (right to buy) M - Exercise D 0,63 -8.015 0
2016-01-08 2016-01-08 4 Morrison Jodie Pope TKAI Common Stock M - Exercise D 1,3700 20.000 27 57.566
2016-01-08 2016-01-08 4 Morrison Jodie Pope TKAI Common Stock M - Exercise D 0,6300 8.015 5 37.566
2015-12-17 2015-12-15 4 Ferrante Karen Jean TKAI Stock Option (right to buy) A - Award D 9,65 62.000 62.000
2015-12-17 2015-12-15 4 Morrison Jodie Pope TKAI Stock Option (right to buy) A - Award D 9,65 189.000 189.000
2015-12-17 2015-12-15 4 Kalowski Lee TKAI Stock Option (right to buy) A - Award D 9,65 62.000 62.000
2015-12-17 2015-12-15 4 McBride John S. TKAI Stock Option (right to buy) A - Award D 9,65 62.000 62.000
2015-12-17 2015-12-15 4 Quirk Gerald E TKAI Stock Option (right to buy) A - Award D 9,65 62.000 62.000
2015-11-12 2015-11-11 4 Buckley Stephen Jr. TKAI Common Stock P - Purchase D 11,2500 3.000 34 3.000
2015-09-22 2015-09-21 4 McBride John S. TKAI Stock Option (right to buy) M - Exercise D 4,19 -13.500 186.678
2015-09-22 2015-09-21 4 McBride John S. TKAI Common Stock S - Sale D 14,0100 -13.500 -189 0
2015-09-22 2015-09-21 4 McBride John S. TKAI Common Stock M - Exercise D 4,1900 13.500 57 13.500
2015-09-08 2015-09-08 4 Kalowski Lee TKAI Common Stock S - Sale D 13,1300 -4.668 -61 40.953
2015-09-04 2015-09-02 4 Kalowski Lee TKAI Common Stock S - Sale D 12,9600 -2.158 -28 45.621
2015-07-30 2015-07-29 4 Morrison Jodie Pope TKAI Stock Option (right to buy) M - Exercise D 1,37 -3.000 57.878
2015-07-30 2015-07-29 4 Morrison Jodie Pope TKAI Stock Option (right to buy) M - Exercise D 0,63 -7.000 8.015
2015-07-30 2015-07-29 4 Morrison Jodie Pope TKAI Stock Option (right to buy) M - Exercise D 1,58 -564 312.736
2015-07-30 2015-07-29 4 Morrison Jodie Pope TKAI Common Stock M - Exercise D 1,3700 3.000 4 29.551
2015-07-30 2015-07-29 4 Morrison Jodie Pope TKAI Common Stock M - Exercise D 0,6300 7.000 4 26.551
2015-07-30 2015-07-29 4 Morrison Jodie Pope TKAI Common Stock S - Sale D 13,7000 -564 -8 19.551
2015-07-30 2015-07-29 4 Morrison Jodie Pope TKAI Common Stock M - Exercise D 1,5800 564 1 20.115
2015-07-30 2015-07-28 4 Morrison Jodie Pope TKAI Stock Option (right to buy) M - Exercise D 1,58 -12.000 313.300
2015-07-30 2015-07-28 4 Morrison Jodie Pope TKAI Common Stock S - Sale D 13,7000 -12.000 -164 19.551
2015-07-30 2015-07-28 4 Morrison Jodie Pope TKAI Common Stock M - Exercise D 1,5800 12.000 19 31.551
2015-07-24 2015-07-22 4 Morrison Jodie Pope TKAI Stock Option (right to buy) M - Exercise D 0,63 -7.426 15.015
2015-07-24 2015-07-22 4 Morrison Jodie Pope TKAI Stock Option (right to buy) M - Exercise D 2,31 -2.574 0
2015-07-24 2015-07-22 4 Morrison Jodie Pope TKAI Common Stock M - Exercise D 0,6300 7.426 5 19.551
2015-07-24 2015-07-22 4 Morrison Jodie Pope TKAI Common Stock M - Exercise D 2,3100 2.574 6 12.125
2015-07-17 2015-07-15 4 Novartis Bioventures Ltd TKAI Common Stock S - Sale D 14,2580 -3.566 -51 4.493.458
2015-07-15 2015-07-14 4 Novartis Bioventures Ltd TKAI Common Stock S - Sale D 14,4100 -27.861 -401 4.497.024
2015-07-15 2015-07-13 4 Novartis Bioventures Ltd TKAI Common Stock S - Sale D 14,2020 -20.611 -293 4.524.885
2015-06-30 2015-06-29 4 Morrison Jodie Pope TKAI Stock Option (right to buy) M - Exercise D 1,58 -8.000 325.300
2015-06-30 2015-06-29 4 Morrison Jodie Pope TKAI Common Stock S - Sale D 13,7000 -8.000 -110 9.551
2015-06-30 2015-06-29 4 Morrison Jodie Pope TKAI Common Stock M - Exercise D 1,5800 8.000 13 17.551
2015-06-30 2015-06-26 4 Morrison Jodie Pope TKAI Stock Option (right to buy) M - Exercise D 1,58 -8.000 333.300
2015-06-30 2015-06-26 4 Morrison Jodie Pope TKAI Common Stock S - Sale D 13,8300 -8.000 -111 9.551
2015-06-30 2015-06-26 4 Morrison Jodie Pope TKAI Common Stock M - Exercise D 1,5800 8.000 13 17.551
2015-06-24 2015-06-24 4 McBride John S. TKAI Stock Option (right to buy) M - Exercise D 4,19 -300 200.178
2015-06-24 2015-06-24 4 McBride John S. TKAI Common Stock S - Sale D 14,2000 -300 -4 0
2015-06-24 2015-06-24 4 McBride John S. TKAI Common Stock M - Exercise D 4,1900 300 1 300
2015-06-24 2015-06-23 4 McBride John S. TKAI Stock Option (right to buy) M - Exercise D 4,19 -6.700 200.478
2015-06-24 2015-06-23 4 McBride John S. TKAI Common Stock S - Sale D 14,0000 -6.700 -94 0
2015-06-24 2015-06-23 4 McBride John S. TKAI Common Stock M - Exercise D 4,1900 6.700 28 6.700
2015-06-24 2015-06-22 4 McBride John S. TKAI Stock Option (right to buy) M - Exercise D 4,19 -2.000 207.178
2015-06-24 2015-06-22 4 McBride John S. TKAI Common Stock S - Sale D 14,0200 -2.000 -28 0
2015-06-24 2015-06-22 4 McBride John S. TKAI Common Stock M - Exercise D 4,1900 2.000 8 2.000
2015-06-19 2015-06-17 4 BARBERICH TIMOTHY J TKAI Stock Option (right to buy) A - Award D 14,04 12.000 12.000
2015-06-19 2015-06-17 4 Harrison Seth Loring TKAI Stock Option (right to buy) A - Award D 14,04 12.000 12.000
2015-06-19 2015-06-17 4 Buckley Stephen Jr. TKAI Stock Option (right to buy) A - Award D 14,04 12.000 12.000
2015-06-19 2015-06-17 4 Yanchik Joseph A., III TKAI Stock Option (right to buy) A - Award D 14,04 12.000 12.000
2015-06-19 2015-06-17 4 Kessler David A. TKAI Stock Option (right to buy) A - Award D 14,04 12.000 12.000
2015-06-18 2015-06-16 4 Novartis Bioventures Ltd TKAI Common Stock S - Sale D 14,2700 -1.120 -16 4.545.496
2015-06-16 2015-06-12 4 Novartis Bioventures Ltd TKAI Common Stock S - Sale D 14,2000 -5.919 -84 4.561.393
2015-06-16 2014-06-15 4 Novartis Bioventures Ltd TKAI Common Stock S - Sale D 14,2000 -14.777 -210 4.546.616
2015-06-12 2015-06-11 4 Novartis Bioventures Ltd TKAI Common Stock S - Sale D 14,2000 -27.875 -396 4.567.312
2015-05-28 2015-05-26 4 Quirk Gerald E TKAI Stock Option (right to buy) A - Award D 10,81 214.605 214.605
2015-04-20 2015-04-16 4 Kalowski Lee TKAI Common Stock S - Sale D 13,0000 -4.567 -59 47.779
2015-04-13 3 Cohen Cheryl TKAI No securities are beneficially owned D 0
2015-04-13 2015-04-09 4 Cohen Cheryl TKAI Stock Option (right to buy) A - Award D 11,08 25.000 25.000
2015-04-06 2015-04-02 4 Kalowski Lee TKAI Common Stock S - Sale D 11,4500 -2.258 -26 52.346
2015-03-20 2015-03-19 4 Novartis Bioventures Ltd TKAI Common Stock S - Sale D 14,5000 -46.141 -669 4.595.187
2015-03-20 2015-03-18 4 Novartis Bioventures Ltd TKAI Common Stock S - Sale D 14,5000 -3.000 -44 4.641.328
2015-01-12 3 Buckley Stephen Jr. TKAI No securities are beneficially owned D 0
2015-01-12 2015-01-08 4 Buckley Stephen Jr. TKAI Stock Option (right to buy) A - Award D 14,49 25.000 25.000
2014-10-17 2014-10-15 4 Morrison Jodie Pope TKAI Stock Option (right to buy) A - Award D 13,25 134.134 134.134
2014-10-17 2014-10-15 4 McBride John S. TKAI Stock Option (right to buy) A - Award D 13,25 50.671 50.671
2014-09-24 2014-09-22 4 Satter Muneer A See footnote. TKAI Series E Preferred Stock C - Conversion I -8.013.003 0
2014-09-24 2014-09-22 4 Satter Muneer A See footnote. TKAI Series D-3 Preferred Stock C - Conversion I -3.931.085 0
2014-09-24 2014-09-22 4 Satter Muneer A See footnote. TKAI Series D-2 Preferred Stock C - Conversion I -457.728 0
2014-09-24 2014-09-22 4 Satter Muneer A See footnote. TKAI Series D-1 Preferred Stock C - Conversion I -4.577.315 0
2014-09-24 2014-09-22 4 Satter Muneer A See footnote. TKAI Common Stock P - Purchase I 15,0000 150.000 2.250 1.771.688
2014-09-24 2014-09-22 4 Satter Muneer A See footnote. TKAI Common Stock C - Conversion I 1.621.688 1.621.688
2014-09-24 2014-09-22 4 Harrison Seth Loring See footnote. TKAI Series E Preferred Stock C - Conversion I -24.199.308 0
2014-09-24 2014-09-22 4 Harrison Seth Loring See footnote. TKAI Series D-3 Preferred Stock C - Conversion I -24.046.035 0
2014-09-24 2014-09-22 4 Harrison Seth Loring See footnote. TKAI Series D-2 Preferred Stock C - Conversion I -1.539.643 0
2014-09-24 2014-09-22 4 Harrison Seth Loring See footnote. TKAI Series D-1 Preferred Stock C - Conversion I -8.711.335 0
2014-09-24 2014-09-22 4 Harrison Seth Loring See footnote. TKAI Series C Preferred Stock C - Conversion I -14.604.833 0
2014-09-24 2014-09-22 4 Harrison Seth Loring See footnote. TKAI Series B-2 Preferred Stock C - Conversion I -644.786 0
2014-09-24 2014-09-22 4 Harrison Seth Loring See footnote. TKAI Series B-1 Preferred Stock C - Conversion I -798.067 0
2014-09-24 2014-09-22 4 Harrison Seth Loring See footnote. TKAI Series A Preferred Stock C - Conversion I -4.500.000 0
2014-09-24 2014-09-22 4 Harrison Seth Loring See footnote. TKAI Common Stock P - Purchase I 15,0000 362.500 5.438 7.912.079
2014-09-24 2014-09-22 4 Harrison Seth Loring See footnote. TKAI Common Stock C - Conversion I 7.549.570 7.549.579
2014-09-24 2014-09-22 4 Apple Tree Partners II - Annex, L.P. TKAI Series E Preferred Stock C - Conversion D -24.199.308 0
2014-09-24 2014-09-22 4 Apple Tree Partners II - Annex, L.P. TKAI Series D-3 Preferred Stock C - Conversion D -10.675.613 0
2014-09-24 2014-09-22 4 Apple Tree Partners II - Annex, L.P. TKAI Common Stock P - Purchase D 15,0000 237.500 3.562 3.568.438
2014-09-24 2014-09-22 4 Apple Tree Partners II - Annex, L.P. TKAI Common Stock C - Conversion D 3.330.938 3.330.938
2014-09-24 2014-09-22 4 Morrison Jodie Pope TKAI Stock Option (right to buy) A - Award D 1,58 165.251 165.251
2014-09-24 2014-09-22 4 Novartis Bioventures Ltd TKAI Series E Preferred Stock C - Conversion D -15.064.469 0
2014-09-24 2014-09-22 4 Novartis Bioventures Ltd TKAI Series D-3 Preferred Stock C - Conversion D -13.222.826 0
2014-09-24 2014-09-22 4 Novartis Bioventures Ltd TKAI Series D-2 Preferred Stock C - Conversion D -1.539.643 0
2014-09-24 2014-09-22 4 Novartis Bioventures Ltd TKAI Series D-1 Preferred Stock C - Conversion D -15.396.431 0
2014-09-24 2014-09-22 4 Novartis Bioventures Ltd TKAI Common Stock P - Purchase D 15,0000 325.000 4.875 4.644.328
2014-09-24 2014-09-22 4 Novartis Bioventures Ltd TKAI Common Stock C - Conversion D 4.319.328 4.319.328
2014-09-24 2014-09-22 4 BARBERICH TIMOTHY J TKAI Series E Preferred Stock C - Conversion D -809.955 0
2014-09-24 2014-09-22 4 BARBERICH TIMOTHY J TKAI Series D-3 Preferred Stock C - Conversion D -457.731 0
2014-09-24 2014-09-22 4 BARBERICH TIMOTHY J TKAI Common Stock C - Conversion D 121.077 121.077
2014-09-24 2014-09-22 4 APPLE TREE PARTNERS II LP TKAI Series D-3 Preferred Stock C - Conversion D -13.370.422 0
2014-09-24 2014-09-22 4 APPLE TREE PARTNERS II LP TKAI Series D-2 Preferred Stock C - Conversion D -1.539.643 0
2014-09-24 2014-09-22 4 APPLE TREE PARTNERS II LP TKAI Series D-1 Preferred Stock C - Conversion D -8.711.335 0
2014-09-24 2014-09-22 4 APPLE TREE PARTNERS II LP TKAI Series C Preferred Stock C - Conversion D -14.604.833 0
2014-09-24 2014-09-22 4 APPLE TREE PARTNERS II LP TKAI Series B-2 Preferred Stock C - Conversion D -644.786 0
2014-09-24 2014-09-22 4 APPLE TREE PARTNERS II LP TKAI Series B-1 Preferred Stock C - Conversion D -798.067 0
2014-09-24 2014-09-22 4 APPLE TREE PARTNERS II LP TKAI Series A Preferred Stock C - Conversion D -4.500.000 0
2014-09-24 2014-09-22 4 APPLE TREE PARTNERS II LP TKAI Common Stock C - Conversion D 4.218.632 4.218.641
2014-09-24 3 Apple Tree Partners IV, L.P. TKAI Common Stock D 250.000
2014-09-24 3 Apple Tree Partners IV, L.P. TKAI Common Stock D 250.000
2014-09-18 2014-09-17 4 Kalowski Lee TKAI Stock Option (right to buy) A - Award D 15,00 218.417 218.417
2014-09-18 2014-09-17 4 Kalowski Lee TKAI Common Stock A - Award D 54.604 54.604
2014-09-16 3 Morrison Jodie Pope TKAI Common Stock D 19.102
2014-09-16 3 Morrison Jodie Pope TKAI Common Stock D 19.102
2014-09-16 3 APPLE TREE PARTNERS II LP TKAI Common Stock D 18
2014-09-16 3 APPLE TREE PARTNERS II LP TKAI Common Stock D 18
2014-09-16 3 Yanchik Joseph A., III TKAI Common Stock D 51.092
2014-09-16 3 Yanchik Joseph A., III TKAI Common Stock D 51.092
2014-09-16 3 Williams Martin D TKAI Common Stock D 337.700
2014-09-16 3 Williams Martin D TKAI Common Stock D 337.700
2014-09-16 3 Harrison Seth Loring See footnote. TKAI Common Stock I 212.712
2014-09-16 3 Harrison Seth Loring TKAI Common Stock D 425.397
2014-09-16 3 Harrison Seth Loring See footnote. TKAI Common Stock I 212.712
2014-09-16 3 Harrison Seth Loring TKAI Common Stock D 425.397
P
Piața deschisă sau achiziția privată de titluri nederivate sau derivate
S
Piața deschisă sau vânzarea privată a titlurilor de valoare nederivate sau derivate
A
Acordarea, atribuirea sau alte achiziții de valori mobiliare de la companie (cum ar fi o opțiune)
C
Conversia derivatei
D
Vânzarea sau transferul de valori mobiliare înapoi către companie
F
Plata prețului de exercițiu sau a obligației fiscale folosind o parte din titlurile de valoare primite de la companie
G
Donarea de valori mobiliare de către sau către persoane din interior
K
Swap-uri de acțiuni și tranzacții similare de acoperire împotriva riscurilor
M
Exercitarea sau conversia titlurilor derivate primite de la companie (cum ar fi o opțiune)
V
O tranzacție raportată voluntar pe Formularul 4
J
Altele (însoțite de o notă de subsol care descrie tranzacția)
How Much do you Like Fintel?
Please share your opinion of our service!
Excellent Bad
Other Listings
DE:2TK 2,92 EUR
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista